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The antipsychotic drug olanzapine is widely prescribed to treat schizophrenia and other psychotic
disorders. However, it often causes unwanted side effects, including diabetes, due to disruption of
insulin-dependant glucose metabolism through a mechanism yet to be elucidated. To determine
if olanzapine can affect the ﬁrst step in glucose metabolism – glucose transport inside cells – we
investigated the effect of this drug on the transport activity of a model glucose transporter. The glu-
cose transporter from Staphylococcus epidermidis (GlcPSe) is speciﬁc for glucose, inhibited by various
human glucose transporter (GLUT) inhibitors, has high sequence and structure homology to GLUTs,
and is readily amenable to transport assay, mutagenesis, and computational modeling. We found
that olanzapine inhibits glucose transport of GlcPSe with an IC50 0.9 ± 0.1 mM. Computational dock-
ing of olanzapine to the GlcPSe structure revealed potential binding sites that were further examined
through mutagenesis and transport assay to identify residues important for olanzapine inhibition.
These investigations suggest that olanzapine binds in a polar region of the cytosolic part of the
transporter, and interacts with residues R129, strictly conserved in all GLUTs, and N136, conserved
in only a few GLUTs, including the insulin-responsive GLUT4. We propose that olanzapine inhibits
GlcPSe by impeding the alternating opening and closing of the substrate cavity necessary for glucose
transport. It accomplishes this by disrupting a key salt bridge formed by conserved residues R129
and E362, that stabilizes the outward-facing conformation of the transporter.
 2015 The Authors. Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Olanzapine is a widely prescribed second generation antipsy-
chotic drug for the treatment of schizophrenia, anxiety and other
mental disorders [1–3]. The use of olanzapine and related drugs
such as clozapine carries the risk of potentially life-altering side
effects including weight gain [4], increased blood cholesterol levels
[5], disruption of insulin-dependent glucose uptake [6], and even
diabetes [7,8]. Side effects due to olanzapine appear dose depen-
dent [9,10]. The negative effects of antipsychotic agents can be
mitigated by administration of general diabetes treatments andweight-loss programs [11], but these medicines can only partially
reverse glucose intolerance and weight gain [12], and they have
additional side effects [13].
Glucose transport in cells is a key step in glucose metabolism. In
humans, facilitated diffusion of glucose and related carbohydrates
is mediated by members of the GLUT (SLC2) family. The fourteen
human GLUTs transport various substrates, exhibit distinct sub-
strate afﬁnity or speciﬁcity and tissue expression, although they
share signiﬁcant sequence homology [14,15]. Crystal structures
are available for only two glucose transporters: the bacterial
glucose/H+ symporter from Staphylococcus epidermidis (GlcPSe) [16]
and human GLUT1 [17]. These structures are similar, with RMSD
for their superposition in the transmembrane helices of less than
1.5 Å (GlcPSe PDB ID: 4LDS, GLUT1 PDB ID: 4PYP). Nevertheless,
the molecular determinants that confer substrate speciﬁcity are
poorly understood.
Insulin-dependent glucose transport in adipocytes and skeletal
muscle is carried out by GLUT4 [18,19]. GLUT4 is located in intra-
cellular vesicles, which are translocated to the plasma membrane
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proposed that interfering with GLUT4 trafﬁcking disrupts glucose
transport [21], leading to the development of diabetes. In adipo-
cytes, olanzapine has an inhibitory effect on insulin-stimulated
glucose transport activity [22]. Interestingly, the side-effects of
some antiretroviral drugs, including indinavir, are similar to those
of olanzapine: weight-gain, obesity, diabetes and others [23].
Furthermore, GLUT4 glucose transport is inhibited by indinavir
[24]. This suggested the possibility that olanzapine may interfere
directly with glucose transport.
Here, the effect of olanzapine on glucose transport was exam-
ined in the bacterial glucose transporter from S. epidermidis,
GlcPSe. It is a convenient glucose transporter model for several rea-
sons: it has high afﬁnity and speciﬁcity for glucose, known crystal
structure, high sequence and structural homology to human glu-
cose transporters (for instance, sequence identity and similarity
to GLUT4 are 31% and 54%, respectively) and it is inhibited by
human GLUT inhibitors [16]. Additionally GlcPSe is amenable
to transport activity assays, mutagenesis and computational
modeling.
We found that olanzapine inhibited glucose transport activity of
GlcPSe. By computational modeling, coupled with site-directed
mutagenesis and transport assay of mutants, we determined the
binding site of olanzapine in GlcPSe and proposed a mechanism
of inhibition. We discuss the implications of these ﬁndings for
human glucose transporters.
2. Materials and methods
2.1. Protein expression
GlcPSe was cloned into the pBAD vector (Invitrogen), containing
C-terminal 6His tag [16]. Required mutations were done by site-
directed mutagenesis using QuickChange kit (Agilent
Technologies). Proteins were expressed in the glucose transporter
deﬁcient Escherichia coli strain JM-1100 (from Yale E. coli Genetic
Stock Center; genotype: Hfr (PO2A)], garB10, fhuA22, galK2(Oc),
k, ompF627(T2R), ptsG23, manXYZ-18, D(his-gnd)79, mgl-50,
fruA10, fadL701(T2R), relA1, thyA111, galP64, pitA10, and spoT).
Cells were grown at 37 C, in Luria Broth medium, with 100 lg/mL
ampicillin. Protein expression was induced with 0.2 mM L-arabinose
when O.D.600nm reached 0.6; cells were grown for 3 more hours.
Cells were harvested by centrifugation at 2500g for 5 min, washed
with 0.1 M Potassium phosphate (KPi) pH 7.5 and 10 mM MgSO4
(buffer A), centrifuged again and ﬁnally resuspended in buffer A
so that O.D.600nm was 2.0. This cell solution was warmed to room
temperature and used for transport assay. Protein expression was
checked by Western Blotting, with penta-His HRP conjugate anti-
body (5 PRIME). Band density of His-tagged proteins in the
Western ﬁlm was analyzed by ImageJ software [25] and Kodak
1D Image Analysis (Eastman Kodak) software, and then the relative
mean values to wild-type were calculated.
2.2. Preparation of right-side-out (RSO) vesicles
The right-side-out (RSO) membrane vesicles of JM1100 E. coli
cells were prepared as described previously [16,26,27]. Cells were
resuspended in 30 mM TrisHCl, pH 8.0, containing sucrose
(30% wt/vol), at a concentration of 1.0 g wet pellet/80 mL, with
lysozyme, and incubated at room temperature for 45 min. The
spheroplasts were harvested by centrifugation at 5000g for
30 min at 4 C. They were resuspended and rapidly diluted into
pre-warmed 50 mM KPi (pH 7.5) with 5 mM DTT. Then 10 mM
K2EDTA was added, and the spheroplasts were incubated for
10 min at 37 C, followed by the addition of 20 mM MgSO4 andanother 10-min incubation. The RSO vesicles were centrifuged at
12,000g for 30 min and then resuspended in ice-cold 0.1 M KPi
(pH 7.5) with 10 mM K2EDTA. Finally, RSO vesicles were recovered
in two steps. Unbroken spheroplasts and cell pellet were removed
by centrifuging at 2500 rpm with a SS-34 rotor for 12 min. The
supernatant was centrifuged at 15,000 rpm with a SS-34 rotor for
15 min, and the resulting pellet was resuspended in buffer A.
This vesicle suspension was frozen in liquid nitrogen and stored
at 80 C until use.
2.3. Radioactive glucose uptake assay
Transport assay was initiated by the addition of 14C-radiola-
beled glucose (Moravek Biochemicals) to 50 lL cells or RSO vesi-
cles (at O.D.600nm of 2.0) in buffer A; after 1 min, the transport
was stopped with ice-chilled quench buffer [0.1 M KPi (pH 5.5)
and 0.1 M LiCl]. For the assay with RSO vesicles, prior to the addi-
tion of glucose, 20 mM ascorbate and 0.2 mM phenazine methosul-
fate were added [28]. The solution was ﬁltered with a cellulose
nitrate membrane ﬁlter (Whatman; 0.4 lm pore size), and the ﬁl-
ter was washed three times with the quench buffer. The membrane
ﬁlter was placed into a vial ﬁlled with BioSafe II scintillation liquid
(Research Products International Corp.), and radioactivity was
quantiﬁed with LS 6500 scintillation counter (Beckman).
Inhibitors were added for 1 min (or other times as speciﬁed) before
the addition of glucose. Kinetic parameters were determined by
nonlinear algorithm plots supplied by Prism (GraphPad
Software). Olanzapine (Cayman Chemical Company) was dissolved
in anhydrous dimethyl sulfoxide (DMSO) at a stock concentration
of 100 mM. DMSO up to 5% concentration in the transport assay
did not affect activity or measurements. To check if olanzapine
inhibition is reversible, we measured transport in RSO vesicles.
2 mM olanzapine was incubated with 1 mL RSO vesicles of
JM1100 E. coli expressing GlcPSe (at O.D.600 nm of 2.0, in buffer A)
for 30 min. Then 50 lL of this solution was used to check the rela-
tive activity as described above. The remaining 950 lL of RSO vesi-
cles-olanzapine solution was centrifuged (16,000g for 3 min, at
room temperature) to pellet the RSO vesicles. Supernatant was
carefully discarded and the pellet was resuspended in 950 lL of
buffer A. The centrifugation and resuspension were repeated once
more. A control sample (RSO vesicles in the absence of olanzapine)
was processed similarly to account for loss in activity due to
repeated centrifugation and re-suspension of the RSO vesicles.
Finally, 50 lL of the washed RSO vesicles was assayed for transport
activity as above.
2.4. Modeling of olanzapine interaction with GlcPSe
To model the binding sites of olanzapine, we used the SiteFinder
function of Molecular Operation Environment (MOE, Chemical
Computing Group) based on the three-dimensional crystal struc-
ture of GlcPSe [16] (PDB ID: 4LDS, www.rcsb.org) in the inward-fac-
ing conformation, and the modeled outward-facing conformation
of GlcPSe based on the E. coli xylose transporter XylE [29] (PDB
ID: 4GC0). Prior to virtual docking, we generated a set of possible
olanzapine conformations, with the Conformational Generation
function of MOE. Virtual docking of olanzapine was carried out
using the Dock function of MOE, with all default parameters in
Triangle Matcher, retaining 105 poses and Alpha HB rescoring
(with equal weights for Hydrogen bonds and Alpha parameter).
Potential docking positions were selected if they had sufﬁcient
space for olanzapine binding and polar and/or charged residues.
Using as a selection criterion the lowest-energy scoring algorithm,
olanzapine docked best in three positions on GlcPSe, all for the
inward-facing conformation of the transporter.
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3.1. Olanzapine inhibits GlcPSe
The effect of olanzapine on glucose transport by GlcPSe was
examined in RSO vesicles. Olanzapine at different concentrations
was incubated with RSO vesicles for 1 min before 14C-glucose
addition. Varying the pre-incubation time of olanzapine with RSO
vesicles from 15 s to 30 min did not affect the inhibition (Fig. 1).
Olanzapine inhibition was concentration dependent, with 1 mM
and 8 mM olanzapine decreasing glucose transport to approxi-
mately 50% and 10%, respectively, compared to uninhibited
GlcPSe. Removal of olanzapine from the reaction solution restored
80% of the activity of GlcPSe, compared to a control sample, consis-
tent with olanzapine inhibition being reversible (Fig. 1).
3.2. Computational determination of olanzapine binding sites in GlcPSe
Possible olanzapine binding sites on GlcPSe were determined
with Molecular Operating Environment (MOE) software by docking
olanzapine to the crystal structure of GlcPSe (PDB ID 4LDS). Docking
of olanzapine to GlcPSe in a predicted outward-facing conformation
did not show any promising possibilities for interaction. Three
binding areas for olanzapine were identiﬁed (Fig. 2A), denoted as
sites 1, 2 and 3. They are located in the cytosolic part of the sub-
strate cavity, formed by helixes 1, 4, 7 and 10, between the N-
and C-terminal 6-helix domains of the transporter (shown as gray
in Fig. 2A). Potential olanzapine-interacting residues were searched
among charged or polar amino acids that have not been reported to
interact with glucose and were within 3.5 Å from olanzapine. The
sites included the following residues: R71 and N191 in site 1 (pur-
ple); R129 and N136 in site 2 (red); and R367 and R369 in site 3
(cyan) (Fig. 2B). These amino acids display varying levels of
sequence conservation compared to human GLUTs (Fig. 2C). Thus
R71, R129 and R369 are completely conserved in GlcPSe and human
GLUTs, whereas N136, N191 or R367 are less conserved.
3.3. Expression and transport activity of GlcPSe mutants
To determine which of the computationally identiﬁed residues
interact with olanzapine, each residue was mutated to alanine,Fig. 1. Olanzapine inhibition of GlcPSe. Transport activity was measured in right-
side-out (RSO) vesicles of JM1100 E. coli expressing GlcPSe. Final concentration of
glucose in the assays was 30 lM. Unless otherwise speciﬁed, RSO vesicles were pre-
incubated with different concentrations of olanzapine for 1 min before glucose
uptake assay. Control is RSO vesicles of JM1100 E. coli cells transformed with empty
pBAD vector. Olanzapine at 2 mM was pre-incubated for different time intervals
(15 s, 30 s and 30 min). For the 2 mM washed sample, RSO vesicles were incubated
with 2 mM olanzapine for 30 min, and then when olanzapine was removed by two
washes: RSO vesicles were pelleted by centrifugation (3 min, 16,000g) and
resuspensed in the same volume of buffer A. Error bars are standard deviations
corresponding to 3 different measurements.and individual mutants were assessed for glucose transport and
subsequent inhibition by olanzapine. All mutants expressed in
similar concentrations in the E. coli JM1100 membrane fractions
(Fig. 3). Glucose transport activity for each mutant, relative to
wild-type GlcPSe, at saturating glucose concentration, is shown in
Fig. 3. R71A and N191A from site 1, R129A from site 2, and
R369A from site 3 were inactive mutants. Nonetheless, N136A
from site 2 and R367A from site 3 retained 57% and 87% of the
wild-type activity, respectively, (Fig. 3) and their olanzapine inhi-
bition could be examined. Michaelis–Menten plots of glucose
transport by N136A and R367A mutants of GlcPSe, in RSO vesicles,
are shown in Fig. 4. For both mutants, Km for glucose transport is
similar to that of wild-type (30 lM, [16]): Km,N136A = 53 ± 5 lM,
Km,R367A = 51 ± 6 lM.
3.4. N136 is involved in olanzapine-induced inhibition of glucose
transport by GlcPSe
Olanzapine inhibition of glucose transport by N136A and R367A
GlcPSe is shown in Fig. 5. Compared to wild-type, there was no sig-
niﬁcant change in olanzapine inhibition of R367A GlcPSe glucose
transport (IC50,R367A = 0.8 ± 0.1 mM, IC50,wild-type = 0.9 ± 0.1 mM). In
contrast, N136A GlcPSe was less sensitive to olanzapine inhibition
(IC50 = 1.5 ± 0.2 mM). Furthermore, at high concentrations of olan-
zapine, the inhibition was also less efﬁcient for N136A GlcPSe
(25% of glucose uptake activity remained compared to 10% activ-
ity remaining in wild-type GlcPSe). Hence, in N136A GlcPSe both
efﬁcacy and potency of olanzapine inhibition were reduced sug-
gesting that N136 may interact with olanzapine.4. Discussion
The side effects of olanzapine treatment are disruptive, ranging
from weight gain to metabolic disorders. The life altering nature of
these side effects can negatively inﬂuence drug compliance, lead-
ing to poor outcomes for mental health patients [30].
Understanding the molecular basis of these side effects could lead
to the development of therapeutic agents with fewer side effects
and improve patient health and outcomes.
This work shows that olanzapine inhibits glucose transport by
GlcPSe, a model for human GLUTs. GlcPSe is a bacterial glucose
transporter with high afﬁnity and speciﬁcity for glucose, inhibited
by human GLUT inhibitors, with high sequence homology to
GLUTs, and known protein structure. Besides its homology to
GLUTs, GlcPSe is an attractive glucose transport model system
because it is tractable to various methods for probing the mecha-
nism of glucose transport inhibition: transport assay in whole cells
or RSO vesicles, mutagenesis, and computational ligand docking
based on crystal structure.
By whole cells or RSO vesicles transport assay, we found that
olanzapine inhibits glucose transport of GlcPSe with IC50 of
0.9 ± 0.1 mM (Fig. 5). Apparently olanzapine easily penetrates the
bacterial cell membrane, as the incubation time of the drug with
the cells or RSO vesicles had no effect on the transport inhibition
(Fig. 1). Computational docking of olanzapine to the GlcPSe struc-
ture indicated that the drug may bind to a polar region in the
cytosolic part of the transporter, in 3 possible areas (Fig. 2A and
B). To identify the olanzapine binding site, we mutated residues
from all 3 putative sites and checked for changes in olanzapine
inhibition. Among the mutants tested, only N136A and R367A
maintained glucose transport activity (Fig. 3). The rest of the pos-
sible interacting residues could be involved in olanzapine binding,
but are essential to transporter function and could not be further
investigated. Olanzapine inhibition of R367A transporter was
undistinguishable from that of the wild-type GlcPSe (Fig. 5). As
Fig. 2. Olanzapine docking in GlcPSe. (A) Predicted olanzapine binding sites are shown in various colors: site 1 (purple), site 2 (red) and site 3 (cyan). (B) Close-up of the
predicted binding sites. Residues that may interact with olanzapine are shown (site 1: R71, E191; site 2: R129, N136; site 3: R367, N369). (C) Alignment of olanzapine binding
site residues of GlcPSe to human GLUTs. The colors in aminoacid sequence conform to the coloring scheme of the predicted binding sites from (A). Figures were drawn using
Chimera [33].
Fig. 3. Glucose transport activity of GlcPSe mutants. Glucose uptake of GlcPSe
mutants relative to wild-type, at 1 mM glucose, in E. coli JM1100 whole-cells assay.
Error bars are standard deviations from 3 different experiments. Western blot of
membranes extracted from cells expressing wild-type and mutants of GlcPSe is
shown below. Difference in band density in the Western ﬁlm was within 30%: 100%,
109%, 117%, 116%, 128%, 104%, 123% and 118%, for wild-type, R71A, R129A, N136A,
N191A, R367A, R369A and E362A GlcPSe, respectively.
Fig. 4. Michaelis–Menten plots for glucose uptake by N136A and R376A GlcPSe.
The experiments were conducted in RSO vesicles. Km,N136A = 53 ± 3 lM
and Km,R376A = 51 ± 6 lM. Error bar is standard deviation from 3 different
measurements.
Fig. 5. Olanzapine inhibition of glucose transport by N136A, R367A and wild-type
GlcPSe. Wild-type and N136A GlcPSe RSO vesicles or R367A GlcPSe cells were pre-
incubated with different concentrations of olanzapine for 1 min, before
measuring glucose uptake. IC50,wild-type = 0.9 ± 0.1 mM; IC50,N136A = 1.5 ± 0.2 mM;
IC50,R367A = 0.8 ± 0.1 mM. Error bar is standard deviation from 3 different
measurements.
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less potently and less efﬁciently than in wild-type GlcPSe (Fig. 5).
Hence, N136 is involved in olanzapine inhibition of GlcPSe.
Interaction of olanzapine with GlcPSe was modeled in the com-
putationally identiﬁed binding site 2, containing R129 and N136(Fig. 6), which were within hydrogen bonding distance from olan-
zapine. The twelve transmembrane helices of GlcPSe are organized
into two 6-helix bundles, with the N- and C-domains related by
pseudo-twofold symmetry. During transport, GlcPSe undergoes sig-
niﬁcant conformational rearrangements between the inward- and
outward-conformations, with the N- and C-domains moving rela-
tive to each other. In the modeled outward-facing conformation
of GlcPSe, based on the homologous protein structure PDB ID
4GC0, R129 (from N-domain) forms a salt bridge with E362 (from
C-domain) (Fig. 6B). Both R129 and E362 are strictly conserved
among all human GLUTs and their mutation to alanine abolishes
glucose transport in GlcPSe (Fig. 3). We propose that the salt bridge
between R129 and E362 stabilizes the outward-facing conforma-
tion and its disruption interferes with glucose transport by
trapping the transporter in the inward-facing conformation.
Olanzapine binding in the proximity of R129, prevents the interac-
tion between R129 and R362, thus, hampering the normal alternat-
ing opening and closing of the substrate cavity, necessary for
glucose transport. Essentially olanzapine locks the transporter in
the inward-facing conformation (Fig. 6C).
This proposed mechanism of olanzapine inhibition allows for
the development of a new drug design strategy. While the
sequence similarity within the transmembrane region among
GLUTs is over 60%, the soluble loops that form the cytoplasmic
and periplasmic faces are variable [16]. Binding of small molecules
to these poorly conserved regions can block the cycling between
Fig. 6. Olanzapine binding site. (A) Predicted olanzapine (OLZ) binding in GlcPSe, corresponding to site 2 from Fig. 2; R129 and N136 are in olanzapine binding site. (B)
Outward-facing conformation of GlcPSe; R129 and E362 form a salt bridge shown as a yellow line, pointed by the red arrow. (C) Inward-facing conformation of GlcPSe with
olanzapine interacting with R129 and N136. Olanzapine prevents the formation of the salt bridge between R129 and E362 that stabilizes the outward-facing conformation,
thus locking the transporter in the inward-facing conformation. (D) Cartoon diagram of olanzapine binding site showing presumed interactions with N136 and R129. Figures
were drawn using Molscript [34] and raster3D [35].
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the opportunity to target one member of a highly conserved family,
like the GLUTs. The structure of a small molecule that binds to the
cytoplasmic or periplasmic poorly conserved regions of the trans-
porter can be tweaked to interact speciﬁcally with a particular
GLUT member. So, the proposed olanzapine inhibition mechanism
can be an inspiration for future drug design that target a certain
GLUT.
Olanzapine inhibition of glucose transport by GlcPSe is reversi-
ble and dose dependent. While metabolic side effects related to
olanzapine treatment are dose dependent [9,10], it is unclear if
these effects persist after cessation of olanzapine. It was claimed
that olanzapine does not affect glucose metabolism in adipocytes
at therapeutic concentrations [31], however, it is not known if this
is true for other types of cells. Since in some organs, mainly liver
and spleen, olanzapine is accumulated at much higher concentra-
tions than in plasma [32] (up to 46-fold difference), it is possible
for the drug to reach levels sufﬁcient for binding to glucose trans-
porters and substantial inhibition of glucose transport in certain
tissues.
This work presents evidence for glucose transport inhibition by
olanzapine, a broadly used antipsychotic. This inhibition may
affect glucose metabolism and lead to related diseases, such as dia-
betes. Accordingly, malfunction of GLUT4 (which has asparagine in
N136 position of GlcPSe) due to olanzapine inhibition would result
in less glucose uptake in muscle or adipocytes cells, eventually
leading to diabetes. This provides a working molecular model of
the causes of olanzapine’s life-altering side effects. Our future
efforts include solving the crystal structure of GlcPSe complexed
with olanzapine, and the study of olanzapine inhibition in various
human glucose transporters. Nevertheless, for drugs that have as
side-effect disruption in glucose metabolism, it is advisable to
examine their potential for interaction with glucose transporters.
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